Annual Report

The report records FY2015 consolidated net sales of ¥404.1 billion and operating income of ¥38.1 billion, with strong fine chemicals performance offsetting weakness in petrochemical products. It highlights the completion of a new mass-production lithium ion capacitor plant and the acquisition of KBI Biopharma as developments in JSR's strategic businesses. The report also describes CSR management through a CSR Committee and four committees operating under its supervision.